Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Sep 4;10:56. doi: 10.1186/1744-8069-10-56

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Guindon et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

mRNA levels of inflammatory cytokines (IL-1β, IL-6, IL-10 and TNFα) in lumbar spinal cord and kidneys. IL-1β (A) mRNA levels are increased in lumbar spinal cord of saline, NaHCO₃ or resveratrol/cisplatin-treated groups relative to the control/saline or vitamin C/cisplatin groups. Resveratrol/cisplatin group exhibited higher IL-1β mRNA levels relative to vitamin C/cisplatin group (A). IL-6, TNFα and IL-10 spinal cord mRNA levels did not differ reliably between groups. (B) In the kidneys, levels of IL-6 and TNFα mRNAs were higher in cisplatin-treated mice compared to the control/saline group. Resveratrol/cisplatin group shows higher IL-6 and TNFα mRNA levels relative to control/saline group. IL-1β and IL-10 mRNA levels in the kidneys did not differ reliably between groups (B). Data are expressed as mean ± s.e.m. (n = 4 per group). *P < 0.041 vs. control/saline or vitamin C/cisplatin (ANOVA, Bonferroni post hoc); + P < 0.046 for resveratrol/cisplatin group vs. vitamin C/cisplatin-treated group (ANOVA, Bonferroni post hoc); ^ P < 0.045 vs. control/saline group (ANOVA, Bonferroni post hoc); # P < 0.043 for resveratrol/cisplatin group vs. control saline group (ANOVA, Bonferroni post hoc).